MapLight Therapeutics, Inc. Segments Disclosure
The Company manages its operations as a reportable segment focused on the research and development of product candidates. The accounting policies of the reportable segment are identical to those described in Note 2. The chief operating decision maker, who manages the Company's operations on a consolidated basis, assesses performance for the reportable segment using consolidated net loss to monitor budget versus actual results and to determine how to effectively allocate the Company's resources. The measure of segment assets is reported on the consolidated balance sheets as total consolidated assets. The following table presents certain financial data for the Company's reportable segment for the years ended December 31, 2025 and 2024 (in thousands):
|
|
Year Ended December 31, |
|
|||||
|
|
2025 |
|
|
2024 |
|
||
Clinical trial expenses |
|
$ |
53,461 |
|
|
$ |
18,180 |
|
Employee-related research and development expenses |
|
|
51,062 |
|
|
|
21,337 |
|
Chemistry, manufacturing and controls expenses |
|
|
18,266 |
|
|
|
11,473 |
|
Preclinical program expenses |
|
|
10,421 |
|
|
|
13,972 |
|
Other research and development expenses |
|
|
5,139 |
|
|
|
3,561 |
|
Employee-related general and administrative expenses |
|
|
21,688 |
|
|
|
7,457 |
|
Professional fees and other general and administrative expenses |
|
|
9,046 |
|
|
|
6,966 |
|
Other segment items(1) |
|
|
(7,931 |
) |
|
|
(5,366 |
) |
Net loss |
|
$ |
161,152 |
|
|
$ |
77,580 |
|
About Segments Disclosures
Segment disclosures break a company into its reportable operating units, revealing revenue, profit, and asset allocation that consolidated financial statements obscure. Under ASC 280, segments must match how the chief operating decision maker views the business, providing a window into internal management structure and resource allocation priorities.
Key signals: compare segment margins to identify which units drive profitability and which destroy value. Watch for changes in the number of reportable segments — segment aggregation or disaggregation often coincides with strategic shifts or attempts to obscure declining performance. Intersegment elimination patterns reveal internal pricing practices. The reconciliation between segment totals and consolidated figures exposes corporate overhead allocation and unallocated items. Geographic revenue concentration highlights regulatory and currency exposure. Compare segment-level capital expenditure against segment revenue to assess where management is investing for future growth versus harvesting existing assets.